Payment overview · 2025
General Payments
$95.99
6 reported records · 5 companies
Healthcare provider profile · identity verified
Kenneth Arlin Mcvey, DO
Allopathic & Osteopathic Physicians|Family Medicine · CEDAR BLUFF, VA · NPI 1316443922
Verified facts
What the public records show
CMS Open Payments records show Kenneth Arlin Mcvey, DO received $95.99 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 32.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.94 | 32.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.24 | 23.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.15 | 15.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.16 | 14.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.50 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $95.99 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.24 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.15 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 39 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 569 | 130 |
| Atorvastatin Calcium | Atorvastatin Calcium | 528 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 468 | 102 |
| Omeprazole | Omeprazole | 439 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 410 | 95 |
| Montelukast Sodium | Montelukast Sodium | 368 | 70 |
| Losartan Potassium | Losartan Potassium | 359 | 84 |
| Furosemide | Furosemide | 348 | 95 |
| Gabapentin | Gabapentin | 345 | 57 |
| Hydrochlorothiazide | Hydrochlorothiazide | 272 | 68 |
| Simvastatin | Simvastatin | 249 | 64 |
| Metformin Hcl | Metformin Hcl | 216 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 208 | 53 |
| Amitriptyline Hcl | Amitriptyline Hcl | 205 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 41 |
| Prednisone | Prednisone | 202 | 110 |
| Potassium Chloride | Potassium Chloride | 200 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 43 |
| Trazodone Hcl | Trazodone Hcl | 189 | 53 |
| Carvedilol | Carvedilol | 177 | 33 |
| Eliquis | Apixaban | 173 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 168 | 43 |
| Ezetimibe | Ezetimibe | 152 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 151 | 44 |
| Famotidine | Famotidine | 148 | 43 |
| Torsemide | Torsemide | 133 | 27 |
| Sertraline Hcl | Sertraline Hcl | 128 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 126 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 23 |
| Atenolol | Atenolol | 125 | 30 |
| Allopurinol | Allopurinol | 123 | 33 |
| Chlorthalidone | Chlorthalidone | 122 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 122 | 20 |
| Metformin Hcl Er | Metformin Hcl | 118 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 37 |
| Valsartan | Valsartan | 116 | 25 |
| Meloxicam | Meloxicam | 112 | 24 |
| Celecoxib | Celecoxib | 110 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 24 |
| Donepezil Hcl | Donepezil Hcl | 107 | 22 |
| Alprazolam | Alprazolam | 103 | 21 |
| Glimepiride | Glimepiride | 98 | 26 |
| Mounjaro | Tirzepatide | 97 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 26 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 93 | 18 |
| Buspirone Hcl | Buspirone Hcl | 92 | 28 |
| Farxiga | Dapagliflozin Propanediol | 92 | 17 |
| Pregabalin | Pregabalin | 92 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 87 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 82 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 15 |
| Ibuprofen | Ibuprofen | 79 | 21 |
| Cefdinir | Cefdinir | 75 | 57 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 18 |
| Lorazepam | Lorazepam | 75 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 17 |
| Tramadol Hcl | Tramadol Hcl | 74 | 18 |
| Ozempic | Semaglutide | 72 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 71 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 12 |
| Rybelsus | Semaglutide | 66 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 65 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 64 | 14 |
| Glipizide | Glipizide | 61 | 15 |
| Alendronate Sodium | Alendronate Sodium | 60 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 11 |
| Ondansetron Odt | Ondansetron | 58 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 13 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 17 |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Lansoprazole | Lansoprazole | 54 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 53 | 16 |
| Levofloxacin | Levofloxacin | 50 | 41 |
| Spironolactone | Spironolactone | 50 | 15 |
| Jardiance | Empagliflozin | 49 | 14 |
| Januvia | Sitagliptin Phosphate | 48 | 13 |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 11 |
| Trulicity | Dulaglutide | 44 | 14 |
| Baclofen | Baclofen | 43 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Sucralfate | Sucralfate | 42 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 18 |
| Azelastine Hcl | Azelastine Hcl | 38 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Finasteride | Finasteride | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 16 |
| Linzess | Linaclotide | 31 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 17 |
| Ibu | Ibuprofen | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 28 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 22 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Colchicine | Colchicine | 27 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Nystatin | Nystatin | 25 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Digoxin | Digoxin | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Naproxen | Naproxen | 22 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Clonazepam | Clonazepam | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 12 |
| Desloratadine | Desloratadine | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Fluorouracil | Fluorouracil | 15 | 14 |
| Klor-Con M20 | Potassium Chloride | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Cabergoline | Cabergoline | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Oxazepam | Oxazepam | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Saxagliptin Hcl | Saxagliptin Hcl | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $95.99 · 6 records | Novo Nordisk Inc | NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, UBRELVY, XIFAXAN, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error